GalNAc-L96：高效RNA靶向递送的关键分子 ...

RNAi therapeutics have shown great success with multiple US Food and Drug Administration (FDA)-approved products involving N-acetyl galactosamine (GalNAc)-conjugated siRNAs to treat liver-targeted ...

为解决肝癌治疗难题，复旦大学附属肿瘤医院的研究人员开展 FAM99B 相关研究。发现 FAM99B 可抑制核糖体生成和肝癌进展，GalNAc - FAM99B65 - 146 有治疗潜力。该研究为肝癌治疗提供新思路，值得科研人员阅读。 复旦大学附属肿瘤医院（Fudan University Shanghai Cancer Center ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first ...